Background: Pulmonary rehabilitation (PR) is mandatory before bronchoscopy lung volume reduction (BLVR); there is scant information about its efficacy post-BLVR. We retrospectively evaluated pulmonary function (PF) and disability in patients pre/post-BLVR and its additive effect on an intensive PR program post-BLVR vs matched non-BLVR controls. We analyzed changes within BLVR patients according to presence or not of atelectasis.
Methods: We compared PF and exercise tolerance (6-min walk test, 6MWT) in 39 BLVR patients (FEV% pred. 28.9 ± 1.5; RV% pred. 236.1 ± 7.7) pre-/post-BLVR, and vs. 32 controls (FEV% pred. 32.7 ± 1.5; RV % pred. 217.8 ± 8.3) before and after PR.
Results: BLVR patients showed a greater improvement than controls in PF (difference between groups: 3.8 for FEV% pred., p = 0.043; -20.5 for RV % pred., p = 0.02) and 6MWT response rate (12/39 vs. 1/39 subjects, p = 0.003). Both groups further improved significantly 6MWT after PR without a significant difference between groups. Atelectasis after BLVR mainly accounted for the improvement in FEV% pred, RV% pred. and 6MWT compared to both BLVR without atelectasis and controls.
Conclusion: BLVR improves PF (particularly RV) and exercise tolerance, patients with lobar exclusion being the best improvers. PR following BLVR yields a further improvement in exercise tolerance in both (atelectasis and non-atelectasis) subgroups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rmed.2018.09.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Widening the selection criteria for lung volume reduction surgery.
Eur Respir J
January 2025
Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium
https://bit.ly/4eWTNy8
View Article and Find Full Text PDFClinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED.
Health Qual Life Outcomes
December 2024
Department of Research and Development, Hornerheide 1, 6085 NM, Ciro, Horn, The Netherlands.
Rationale: Knowledge about the clinical importance of patient-reported outcome measures (PROMs) in severe asthma is limited.
Objectives: To assess whether and to what extent asthma exacerbations affect changes in PROMS over time and asthma-specific PROMs can predict exacerbations in adult patients with severe asthma in usual care.
Methods: Data of 421 patients with severe asthma (62% female; mean age 51.
Long-Term Outcome of Childhood Asthma: Characterizing COPD-A and COPD-C Subtypes in Adulthood.
J Asthma Allergy
December 2024
Respiratory Research Unit Hvidovre, Department of Respiratory Medicine, Copenhagen University Hospital - Hvidovre, Hvidovre, Denmark.
Background And Aim: Asthma in early life has been linked to subsequent development of COPD and according to GOLD 2023 COPD may be divided into distinct subtypes. We aimed to investigate factors associated with the GOLD classification COPD-A (asthma in childhood) and COPD-C (tobacco exposure) in a cohort of adults with a history of severe childhood asthma.
Patients And Methods: In a cohort of Danish adults with a history of severe childhood asthma and a previous 4-month stay during childhood at the asthma care facility in Kongsberg, Norway, we divided participants in a long-term follow-up examination into COPD-A and COPD-C, defined as post-bronchodilator FEV/FVC < 0.
The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases.
BMC Pulm Med
December 2024
Department of respiratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Background: Dupilumab inhibiting the signaling of interleukin(IL)-4 and IL-13 was recommended for the treatment of severe asthma in children ≥ 6 years old according to the Global Initiative for Asthma (GINA,2024).This study aimed to analyse the efficacy and safety of dupilumab in paediatric patients with moderate-to-severe asthma and comorbid type 2 inflammatory disease in a real-world population.
Methods: We evaluated the medical records of paediatric patients with moderate-to-severe asthma and comorbid type 2 inflammatory diseases, such as atopic dermatitis (AD) and allergic rhinitis (AR), receiving dupilumab treatment.
New Classifications of COPD Severity Based on Impulse Oscillometry: A SAIO Grade Base on ECOPD Cohort in China.
Arch Bronconeumol
October 2024
Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Guangzhou National Laboratory, Guangzhou, China. Electronic address:
Background: Recently, the severities of chronic obstructive pulmonary disease (COPD) can also be assessed by impulse oscillometry (IOS). This study aimed to explore a new classification of severity of COPD based on IOS and associations with acute exacerbations (AE) in patients with COPD.
Methods: The data of our study were based on the baseline and 2-year follow-up data of a prospective cohort in China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!